10-25% of the patients in placebo cohorts in NASH clinical trials (0.5-2 years) have fibrosis score reductions. What could be mechanistically responsible for improvements in fibrosis scores in such high proportions of untreated patients? Reduced caloric intake can minimize hepatic lipid burden, yet weight loss was not reported at the end of these studies. Cyclical alterations in caloric intake, or yo-yo dieting, maybe able to explain the clinical observations.
By Lisl KM Shoda, Christina Battista, Grant T Generaux, and Scott Q Siler
Presented at the American Association for the Study of Liver Disease November 12th-15th, 2021